Compare DDL & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DDL | TECX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | China | United States |
| Employees | N/A | 60 |
| Industry | Catalog/Specialty Distribution | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.3M | 554.1M |
| IPO Year | 2021 | N/A |
| Metric | DDL | TECX |
|---|---|---|
| Price | $2.70 | $28.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $75.20 |
| AVG Volume (30 Days) | ★ 436.4K | 162.6K |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $14.86 | N/A |
| P/E Ratio | $16.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $14.39 |
| 52 Week High | $3.41 | $35.99 |
| Indicator | DDL | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 46.78 |
| Support Level | $2.58 | $28.31 |
| Resistance Level | $2.78 | $31.88 |
| Average True Range (ATR) | 0.06 | 1.32 |
| MACD | 0.02 | -0.34 |
| Stochastic Oscillator | 72.09 | 13.70 |
Dingdong (Cayman) Ltd is the fastest growing on-demand e-commerce company in China. The company directly provides users and households with fresh produce, meat and seafood, and other daily necessities through a convenient shopping experience supported by an extensive self-operated frontline fulfillment grid. It recognizes revenues from product sales of fresh groceries and other daily necessities through Dingdong Fresh APP and mini-programs and membership services.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.